RecruitingNCT01258231
Identification of Genomic Predictors of Adverse Events After Cardiac Surgery
Sponsor
Brigham and Women's Hospital
Enrollment
4,000 participants
Start Date
Aug 1, 2000
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to identify genetic causes of adverse events after cardiac surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction and heart failure. Patients undergoing heart surgery at Brigham and Women's Hospital and Texas Heart Institute are eligible to participate.
Eligibility
Min Age: 20 YearsMax Age: 90 Years
Inclusion Criteria2
- Undergoing heart surgery
- Willing to provide consent
Exclusion Criteria1
- Enrolled in a concurrent drug or device trial that precludes concurrent enrollment
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01258231
Related Trials
Mind Your Heart-II
NCT054311921 location
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations